EMERYVILLE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. today announced that its President and Chief Executive Officer, Paul E. Freiman, will present a corporate overview at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at 9:25 a.m. on November 7, 2005 in New York City.
Following Mr. Freiman’s presentation, Dr. David E. Levy, Vice President, Clinical Development for NTII, will participate in a Stroke Focus Panel discussion at 11:15 a.m.
Both the presentation and the Stroke Focus Panel will be webcast at the link below and available for 90 days after the event on the NTII website at www.ntii.com
http://www.shareholder.com/ntii/medialist.cfm
Listeners are encouraged to visit the website at least 15 minutes prior to the beginning of the scheduled presentation to register and to download and install any necessary audio software.
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc. NTI is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company’s strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and which can be rapidly commercialized. NTI’s experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy and seeks partnerships with pharmaceutical and biotechnology companies to complete development and marketing of its product candidates.
Neurobiological Technologies, Inc.
CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies,Inc., +1-510-595-6000; or Cheryl Schneider, VP, Investor Relations, or JeffMyhre, VP, Editorial, both of Porter, Le Vay & Rose, Inc., +1-212-564-4700,for Neurobiological Technologies, Inc.
Web site: http://www.ntii.com/
